Zobrazeno 1 - 10
of 1 055
pro vyhledávání: '"Ombitasvir"'
Publikováno v:
Exploration of Medicine, Vol 4, Iss 1, Pp 33-44 (2023)
Aim: Utilizing the therapeutic potentials of previously approved medications against a new target or pharmacological response is known as drug repurposing. The health and scientific communities are under continual pressure to discover new compounds w
Externí odkaz:
https://doaj.org/article/b86d4860684e43e4ab084df568a690ea
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pharmacology Research & Perspectives, Vol 10, Iss 6, Pp n/a-n/a (2022)
Abstract The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conducted to evaluate the pharmacokinetics, safety, and tolerabil
Externí odkaz:
https://doaj.org/article/0dfb66dcc061425485027c359f9261f7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nahla Mohamed Teama, Waleed Anwar Abdel-Mohsen, Ossama Ashraf Ahmed, Sarah Mohamed El Sayed, Ahmed Mohamed ElGhandour
Publikováno v:
Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Background Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. T
Externí odkaz:
https://doaj.org/article/d99beeee59db4148b6bc99c8f55f5e86
Autor:
Yusheng Jie, Chaoshuang Lin, Jing Yuan, Zhixin Zhao, Yujuan Guan, Yuanping Zhou, Xiaohui Zhou, Bihui Zhong, Yinong Ye, Lihua Zhang, Ling Tao, Jianping Li, Xiaohong Zhang, Yutian Chong
Publikováno v:
Liver Research, Vol 4, Iss 3, Pp 153-158 (2020)
Background and aim: Real-world data on the effectiveness and safety of treatment with the direct-acting antiviral agent-based regimen are limited on the Chinese mainland. The aim of this study was to conduct a multicenter, prospective, real-world stu
Externí odkaz:
https://doaj.org/article/4fed04a836be40309643c55654932ccb
Autor:
Haruki Uojima, Shuzo Kobayashi, Hisashi Hidaka, Takeshi Kinbara, Tomoaki Fujikawa, Tsuyoshi Nakayama, Hiroki Yamanoue, Takayuki Kanemaru, Tohru Hashimotoh, Ji Hyun Sung, Makoto Kako, Wasaburo Koizumi
Publikováno v:
Annals of Hepatology, Vol 18, Iss 1, Pp 109-115 (2019)
Introduction and aim. We assessed the characteristics of virological response to a combination treatment of ombitasvir, paritaprevir, and ritonavir in hepatitis C virus genotype 1-infected elderly Japanese patients.Material and Methods. This multicen
Externí odkaz:
https://doaj.org/article/750bd767098c45629567bffaad399f35
Publikováno v:
Scripta Medica, Vol 50, Iss 2, Pp 77-81 (2019)
Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection. Methods: This real-life multi-centric study was performed at the Cli
Externí odkaz:
https://doaj.org/article/e5cb3fcdac7043a7b95a6833de97bc06
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Kidney & Blood Pressure Research, Vol 43, Iss 2, Pp 594-605 (2018)
Background/Aims: Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in
Externí odkaz:
https://doaj.org/article/eb14cc8f477340b582de8283135f6fa9